Skip to main content
Elsevier
View Cart

Nicotine Use in Mental Illness and Neurological Disorders

  • 1st Edition, Volume 124 - October 16, 2015
  • Latest edition
  • Editor: Mariella De Biasi
  • Language: English

Nicotine Use in Mental Illness and Neurological Disorders, a volume in the International Review of Neurobiology series, is a comprehensive overview of the state-of-the-art… Read more

World Book Day celebration

Where learning shapes lives

Up to 25% off trusted resources that support research, study, and discovery.

Explore resources

Description

Nicotine Use in Mental Illness and Neurological Disorders

, a volume in the International Review of Neurobiology series, is a comprehensive overview of the state-of-the-art research into nicotine use in mental illness and neurological disorders. It reviews current knowledge and understanding, also provides a starting point for researchers and practitioners entering the field.

Key features

  • Provides a broad coverage of subject matter
  • Presents a comprehensive overview of the state-of-the-art research into nicotine use in mental illness and neurological disorders
  • Ideal for researchers and practitioners, and those just entering the field

Readership

People working in basic neuroscience, neurology and psychiatry; medical doctors and care givers.

Table of contents

  • Preface
  • Part 1: Introductory chapter
    • Chapter One: Neuronal Nicotinic Acetylcholine Receptor Structure and Function and Response to Nicotine
      • Abstract
      • 1 Introduction
      • 2 Nicotinic Receptor Structure
      • 3 Nicotinic Receptor Channel Gating
      • 4 Cationic Permeability of the Nicotinic Receptor Pore
      • 5 Nicotinic Receptor Response to Nicotine from Tobacco
      • 6 Conclusion
      • Acknowledgment
  • Part 2: Schizophrenia
    • Chapter Two: The Role of Nicotine in Schizophrenia
      • Abstract
      • 1 Introduction
      • 2 Effects of Nicotine on Schizophrenia Endophenotypes and Symptom Domains
      • 3 Nicotinic Receptor Genes in Schizophrenia
      • 4 Development of Nicotinic Agents for the Treatment of Schizophrenia
      • 5 Conclusions
    • Chapter Three: Neuronal α7 Nicotinic Receptors as a Target for the Treatment of Schizophrenia
      • Abstract
      • 1 Introduction
      • 2 The α7 nAChRs
      • 3 The Heteromeric α7-Containing Receptors
      • 4 Localization of the α7 Receptors
      • 5 Allosteric Modulation
      • 6 The α7 Receptors in Brain Circuits
      • 7 α7 Receptors and Schizophrenia
      • 8 α7 and NMDA Receptor Interactions in Schizophrenia
      • 9 α7 Receptors as a Drug Target
      • 10 Effects of α7-Selective Compounds on Behavior
      • 11 Conclusions
    • Chapter Four: Role of the Neuregulin Signaling Pathway in Nicotine Dependence and Co-morbid Disorders
      • Abstract
      • 1 Introduction
      • 2 Known Mechanisms of Neuregulin–ErbB Signaling
      • 3 NRG3: Relevance in Smoking Behavior and Co-morbid Disorders
      • 4 ERBB4: Relevance in Smoking Behavior and Co-morbid Disorders
      • 5 Summary
    • Chapter Five: Effective Cessation Strategies for Smokers with Schizophrenia
      • Abstract
      • 1 Efficacy of Bupropion, as Monotherapy or in Combination with NRT
      • 2 Efficacy of Varenicline
      • 3 Duration of Treatment
      • 4 Behavioral Treatment
      • 5 Treatment Adherence
      • 6 Safety Issues
      • 7 Conclusion
  • Part 3: Mood disorders
    • Chapter Six: Role of the Brain's Reward Circuitry in Depression: Transcriptional Mechanisms
      • Abstract
      • 1 Introduction
      • 2 The NAc Reward Circuit in Mood Regulation
      • 3 Transcriptional and Epigenetic Mechanisms in the NAc in Mood Regulation
      • 4 Future Directions
      • Acknowledgment
    • Chapter Seven: Nicotine Addiction and Psychiatric Disorders
      • Abstract
      • 1 Introduction
      • 2 Nicotine's Effects on ADHD
      • 3 Involvement of nAChRs in Anxiety and Anxiety Disorders
      • 4 Effects of Nicotine Dependence, Withdrawal, and nAChR Regulation on Depression
      • 5 Conclusion
      • Acknowledgment
    • Chapter Eight: The Role of Depression in the Uptake and Maintenance of Cigarette Smoking
      • Abstract
      • 1 The Smoking and Depression Problem
      • 2 Adolescent Smoking Uptake and Depression
      • 3 Smoking Cessation and Depression
      • 4 Targeting Positive Mood May Increase Smoking Cessation Treatment Effectiveness
      • 5 Individual Differences in Cessation Outcome and Treatment Effectiveness
      • 6 Conclusions
  • Part 4: Parkinson's disease
    • Chapter Nine: Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease and Drug-Induced Movement Disorders
      • Abstract
      • 1 Parkinson's Disease Overview
      • 2 Neuroprotection and Parkinson's Disease
      • 3 Nicotine and nAChR Drugs Do Not Improve Parkinsonian Motor Symptoms
      • 4 Nicotine and nAChR Drugs Reduce LIDs
      • 5 Nicotine and nAChR Drugs Reduce Antipsychotic-Induced Tardive Dyskinesias
      • 6 Beneficial Role of Nicotine and nAChR Drugs in Cognition, Depression, and Other Neuropsychiatric Disorders
      • 7 Concluding Remarks
      • Acknowledgment
  • Part 5: Alzheimer's disease
    • Chapter Ten: Nicotinic Cholinergic Mechanisms in Alzheimer's Disease
      • Abstract
      • 1 Homomeric and Heteromeric α7-nAChRs
      • 2 Alterations of α7-nAChR Expressions in AD Animal Models and AD Patients
      • 3 Interaction of Amyloid Beta Peptides (Aβ) and α7-nAChRs
      • 4 Coincident Roles of α7-nAChRs in Aβ Toxicity
      • 5 Roles of α7-nAChRs in Neuronal Hyperexcitation in AD
      • 6 Coincident Roles of α7-nAChRs in AD Pathogenesis
      • 7 Conclusions
  • Index
  • Contents of Recent Volumes

Product details

  • Edition: 1
  • Latest edition
  • Volume: 124
  • Published: October 16, 2015
  • Language: English

About the editor

MD

Mariella De Biasi

Affiliations and expertise
University of Pennsylvania, PA, USA

View book on ScienceDirect

Read Nicotine Use in Mental Illness and Neurological Disorders on ScienceDirect